Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - Kidney International
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its | DDDT
Bardoxolone Methyl | ≥99%(HPLC) | Selleck | IκB/IKK inhibitor
Bardoxolone methyl | 218600-53-4
BARDOXOLONE METHYL
Bardoxolone methyl: drug development for diabetic kidney disease | SpringerLink
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney | American Society of Nephrology
NF-kB Signaling Pathway products from Selleck Chemicals
Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics
Bardoxolone methyl (RTA 402) | Nrf2 Activator | MedChemExpress
Bardoxolone conjugation enables targeted protein degradation of BRD4 | Scientific Reports
Pharmacodynamics of bardoxolone methyl. A, levels of NF- k B, cyclin... | Download Scientific Diagram
Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites | Journal of Medicinal Chemistry
Frontiers | Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies
Frontiers | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages
Bardoxolone methyl (RTA 402) | ≥99%(HPLC) | IκB/IKK inhibitor | AdooQ®
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease - ScienceDirect
Cancers | Free Full-Text | Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer | HTML
Antioxidants | Free Full-Text | Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling | HTML
